Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.
The efficacy of intravenous itraconazole solubilized in hydroxypropyl-beta-cyclodextrin was assessed in a rat model of Aspergillus fumigatus pneumonia. Immunosuppressed rats were infected by intratracheal inoculation of A. fumigatus conidia. Intravenous administration of various doses of itraconazole was started immediately after infection and continued once a day for 7 days. A 10-mg dose of intravenous itraconazole per kg was as effective on survival as 1 mg of amphotericin B per kg daily (a survival rate of 100% in 28 days), while treatment with 1 mg/kg did not increase the survival rate. The 50% lethal dose of intravenous itraconazole given to immunosuppressed and uninfected rats for 7 days was 24.5 mg/kg/day. A microbiological assay to estimate accumulation in tissue after five daily intravenous administrations of itraconazole at 10 mg/kg showed that itraconazole and its active metabolites were present in the lungs for at least 6 h, reaching the MIC as previously described (B. Dupont and E. Drouchet, Rev. Infect. Dis. 9(Suppl. 1):71-76, 1987; A. Espinel-Ingroff, S. Shadomy, and R. J. Gebhart, Antimicrob. Agents Chemother. 26:5-9, 1984). Intravenous itraconazole was considered to be worth evaluating in clinical trials of aspergillosis.
Miyazaki
H M
HM
Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Kohno
S
S
Miyazaki
Y
Y
Mitsutake
K
K
Tomono
K
K
Kaku
M
M
Koga
H
H
Hara
K
K
D000818:Animals; D001228:Aspergillosis / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007165:Immunosuppression Therapy; D007275:Injections, Intravenous; D017964:Itraconazole / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D017964:Itraconazole